Difference between revisions of "CD138"
Jump to navigation
Jump to search
(create) |
|||
| Line 2: | Line 2: | ||
==Positive== | ==Positive== | ||
*[[Plasma cell]]s. | *[[Plasma cell]]s.<ref name=Ref_WMSP554>{{Ref WMSP|554}}</ref> | ||
*[[Plasma cell neoplasm]]. | *[[Plasma cell neoplasm]]. | ||
*Triple negative breast cancer.<ref name=pmid25273930 >{{Cite journal | last1 = Lim | first1 = GH. | last2 = Tan | first2 = PH. | last3 = Jara-Lazaro | first3 = AR. | last4 = Thike | first4 = AA. | last5 = Sim | first5 = WC. | last6 = Yap | first6 = VB. | last7 = Yip | first7 = GW. | title = Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. | journal = Singapore Med J | volume = 55 | issue = 9 | pages = 468-72 | month = Sep | year = 2014 | doi = | PMID = 25273930 }} | *Triple negative breast cancer.<ref name=pmid25273930 >{{Cite journal | last1 = Lim | first1 = GH. | last2 = Tan | first2 = PH. | last3 = Jara-Lazaro | first3 = AR. | last4 = Thike | first4 = AA. | last5 = Sim | first5 = WC. | last6 = Yap | first6 = VB. | last7 = Yip | first7 = GW. | title = Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. | journal = Singapore Med J | volume = 55 | issue = 9 | pages = 468-72 | month = Sep | year = 2014 | doi = | PMID = 25273930 }} | ||
Revision as of 14:35, 8 December 2015
CD138, also known as Syndecan-1, is an immunostain that marks plasma cells.
Positive
- Plasma cells.[1]
- Plasma cell neoplasm.
- Triple negative breast cancer.[2]
See also
References
- ↑ Humphrey, Peter A; Dehner, Louis P; Pfeifer, John D (2008). The Washington Manual of Surgical Pathology (1st ed.). Lippincott Williams & Wilkins. pp. 554. ISBN 978-0781765275.
- ↑ Lim, GH.; Tan, PH.; Jara-Lazaro, AR.; Thike, AA.; Sim, WC.; Yap, VB.; Yip, GW. (Sep 2014). "Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival.". Singapore Med J 55 (9): 468-72. PMID 25273930.
.